See every side of every news story
Published loading...Updated

Genetically Modified Herpes Virus Shows Promise Against Advanced Melanoma

LOS ANGELES COUNTY, CALIFORNIA, JUL 08 – The engineered herpes virus RP1 combined with nivolumab caused tumor shrinkage or disappearance in one-third of advanced melanoma patients in phase 1-2 trials, FDA review pending.

  • Earlier this month, a clinical trial showed RP1 combined with nivolumab shrank tumors in one-third of advanced melanoma patients, with nearly one-sixth experiencing complete disappearance.
  • Driven by resistance, 140 patients with advanced melanoma had limited treatments and only a few years' survival, highlighting the urgent unmet need.
  • Published phase 1-2 data show RP1 combined with nivolumab shrinks tumors in one-third of advanced melanoma patients, with experts highlighting its potential to target cancer beyond injected sites.
  • Following the phase 1-2 success, the FDA granted priority review in January 2025, with a decision due by month’s end, and the phase 3 IGNYTE-3 trial now open.
  • Beyond injected tumors, experts predict RP1 will see broader use than T-VEC, potentially transforming oncolytic virus therapy for hard-to-treat cancers.
Insights by Ground AI
Does this summary seem wrong?

12 Articles

All
Left
1
Center
3
Right
NewScientistNewScientist
Reposted by
Anti-Aging, Acupuncture and Health NewsAnti-Aging, Acupuncture and Health News
Center

Herpes virus could soon be approved to treat severe skin cancer

A cancer-killing virus could soon be approved for use after shrinking tumours in a third of people with late-stage melanoma

·Baltimore, United States
Read Full Article

Treatment of cancer with a virus? This may be an unexpected form, but according to a new study has promising results. A study published in the Journal of Clinical Oncology showed that the virus of herpes when genetically modified can be the solution in the treatment of cancer, in particular in more advanced cases of melanoma, one of the types of skin cancer. The results of the study were presented by Keck Medicine of the University of Southern C…

·Portugal
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 75% of the sources are Center
75% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

NewScientist broke the news in Baltimore, United States on Tuesday, July 8, 2025.
Sources are mostly out of (0)

You have read 1 out of your 5 free daily articles.

Join millions of well-informed readers who use Ground to compare coverage, check their news blindspots, and challenge their worldview.